Close Menu


In two studies, researchers showed the benefit of combining Tecentriq, Cotellic, and Zelboraf and sticking with continuous versus intermittent dosing of targeted drugs.

At the AACR meeting, investigators presented complete data from a Phase II trial that is supporting Novartis' drug approval application with the FDA.

Though the Phase II results from the I-SPY 2 trial showed a potential benefit of the regimen in the neoadjuvant setting, additional data are needed.

Inivata expects to publish initial data on the assay's detection abilities in lung cancer at the American Association for Cancer Research virtual meeting in July.

Researchers are making improvements to viral-DNA detection methods and are exploring applications not just for screening but also disease monitoring.

In two trials in the neoadjuvant setting reported at SABCS, one showed improved rates of pathologic complete response with added immunotherapy, and the other showed no difference.

Investigators at the San Antonio Breast Cancer Symposium reported median progression free survival of 16.4 months for those who got the target dose of the drug.

Investigators provided updated evidence that that the combined treatment prevents more women from relapsing, especially higher-risk node-positive patients.

Chi Van Dang discussed major breakthroughs now moving out into community practice, continued challenges, and promising new areas oncologists may want to watch.

The TATTON study found a combination therapy could treat some EGFR-positive lung cancer patients who developed MET-based resistance, but the best way to gauge MET status isn't yet clear.